Literature DB >> 2448596

Immunoresponses to Neisseria meningitidis epitopes: in vivo analysis of immunocompetent cells involved in suppression of secondary response to phosphorylcholine.

J Faro1, R Seoane, I Lareo, A Eiras, M Schiller, B J Regueiro.   

Abstract

The immune response to phosphorylcholine (PC) antigens has been extensively studied in recent years. Neisseria meningitidis serogroup B M986 (NMB) was recently reported to induce a PC-specific plaque-forming cell (PFC) immuno-response in mice, a characteristic useful for the study of immunomodulating properties of N. meningitidis. With this technique, priming mice with low doses of NMB has been shown greatly to impair their ability, one month after priming, to mount an anti-PC response induced by NMB; this suppression is permanent, does not involve switching from IgM to another immunoglobulin class, transiently affects the T15 idiotype expression and is carrier specific. We report, based on an analysis of spleen cells from NMB-primed mice in an adoptive transfer model, that this suppression does not appear to be mediated by B lymphocytes nor does it seem to be under the direct control of T lymphocytes; rather, it involves radio-resistant cells. Additionally, our results show that NMB modulates the idiotype composition of the anti-phosphorylcholine response, probably by enhancing the expression of so called hapten-augmentable PFC. These results demonstrate that NMB can interfere effectively with the immune response in a variety of ways.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2448596     DOI: 10.1007/bf00194889

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  43 in total

1.  Further improvements in the plaque technique for detecting single antibody-forming cells.

Authors:  A J Cunningham; A Szenberg
Journal:  Immunology       Date:  1968-04       Impact factor: 7.397

2.  Hemolytic plaque inhibition: the physical chemical limits on its use as an affinity assay.

Authors:  C DeLisi
Journal:  J Immunol       Date:  1976-12       Impact factor: 5.422

Review 3.  The IgA1 proteases of pathogenic bacteria.

Authors:  A G Plaut
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

Review 4.  CBA/N immune defective mice; evidence for the failure of a B cell subpopulation to be expressed.

Authors:  I Scher
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Lack of involvement of auto-anti-idiotypic antibody in the regulation of oscillations and tolerance in the antibody response to levan.

Authors:  J R Hiernaux; J Chiang; P J Baker; C Delisi; B Prescott
Journal:  Cell Immunol       Date:  1982-03-01       Impact factor: 4.868

6.  Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors:  L Y Wang; C E Frasch
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  Monoclonal antibodies against Neisseria meningitidis lipopolysaccharide.

Authors:  R J Sugasawara; C Prato; J E Sippel
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

8.  Immunoresponses to Neisseria meningitidis epitopes: immunomodulation by meningococcus B acts on more than one meningococcal surface epitope.

Authors:  J Faro; R Seoane; I Lareo; A Eiras; J Couceiro; B J Regueiro
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

9.  Production of auto-anti-idiotypic antibody during the normal immune response to TNP-Ficoll. II. Hapten-reversible inhibition of anti-TNP plaque-forming cells by immune serum as an assay for auto-anti-idiotypic antibody.

Authors:  E A Goidl; A F Schrater; G W Siskind; G J Thorbecke
Journal:  J Exp Med       Date:  1979-07-01       Impact factor: 14.307

10.  The interaction in vitro between group B meningococci and rabbit polymorphonuclear leukocytes. Demonstration of type specific opsonins and bactericidins.

Authors:  R B Roberts
Journal:  J Exp Med       Date:  1967-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.